Anyone searching for a metabolic health assessment tends to find two kinds of results. One is dense academic literature on metabolic syndrome biomarkers. The other is direct-to-consumer lab companies selling panels by biomarker count. Very little explains what a real, clinically supervised assessment actually involves.
A formal metabolic health assessment is a structured clinical process with three parts:
- A defined set of core markers
- An extended workup when the findings warrant it
- In-person interpretation that turns the numbers into a staged risk picture and a plan
This matters for far more people than those with a diagnosed condition. A UNC Chapel Hill analysis of NHANES data found that only 12.2% of US adults met optimal criteria on all five core metabolic markers without medication. Among adults with obesity, that figure fell to 0.5%.
A 2026 JAMA analysis put the weighted prevalence of metabolic syndrome at 38.7% of US adults, with notable increases among adults 60 and older and non-Hispanic Black individuals. The CDC estimates that 115.2 million adults have prediabetes and 40.1 million have diabetes. Of those with diabetes, 11 million are undiagnosed.
This article explains what a real clinical workup includes and how it differs from an at-home test kit.
The Five Core Markers Every Formal Assessment Starts With
These five markers form the backbone of nearly every clinical metabolic syndrome definition, including NCEP ATP III. The clinical standard is meeting optimal levels on all five without medication, and only about 12.2% of adults do.
Fasting Glucose and HbA1c
The two tests measure different things:
- Fasting glucose is a single, point-in-time blood sugar reading.
- HbA1c reflects average blood sugar over roughly three months.
Clinicians usually draw both together because each fills gaps the other leaves. With 11 million Americans living with diabetes they don’t know about, this pairing is one of the simplest ways to catch problems early.
Triglycerides and HDL Cholesterol
Both are drawn as part of a standard fasting lipid panel during a clinical visit and are read together rather than separately. High triglycerides paired with low HDL is a classic early signal of metabolic strain.
Blood Pressure
Blood pressure is measured in the clinic by trained staff rather than self-reported. It is taken at the same visit as the blood draw, so it is read alongside the lab results instead of relying only on home-device averages. It is one of the five markers in every major metabolic syndrome definition.
Waist Circumference
This simple measurement is one of the strongest surrogate markers for insulin resistance and visceral fat. A nationwide Korean population study found that waist circumference correlated more closely with HOMA-IR, an insulin resistance measure, than BMI did.
Accuracy depends on technique. A trained person needs to measure at the correct landmark in the correct way, something a mailed test kit cannot replicate.
Why the Five-Marker Panel Alone Isn’t the Whole Picture
The 12.2% figure shows how common it is to fall short on at least one marker, even among adults who seem healthy. The five markers can flag a problem, but they cannot fully characterize insulin resistance, organ involvement, or inflammatory burden.
This is where a direct-to-consumer panel stops and a clinical workup continues.
The Extended Clinical Workup: What a Clinic Adds Beyond the Basics
Clinics add further testing when risk factors, history, or initial results call for a closer look. A provider, not an algorithm, chooses which tests to order based on the individual patient. There is no fixed menu.
Fasting Insulin and HOMA-IR
HOMA-IR is calculated from fasting glucose and fasting insulin. Clinicians use it as a proxy for insulin resistance and beta-cell function, which is how well the pancreas produces insulin.
It is often added because glucose and HbA1c can look normal for years while insulin resistance is already developing.
Liver and Kidney Panels
- Liver enzymes are checked because metabolic dysfunction is commonly linked to fatty liver changes.
- Kidney markers, such as eGFR and the urine albumin-creatinine ratio, are included under the cardiovascular-kidney-metabolic view of risk.
That view treats metabolic, cardiovascular, and kidney health as one interconnected system rather than three separate ones.
hs-CRP and Inflammatory Markers
High-sensitivity C-reactive protein (hs-CRP) reflects low-grade, body-wide inflammation, which often rises alongside metabolic dysfunction. A provider may add it when the core markers suggest elevated cardiometabolic risk.
Body Composition Assessment
DEXA or bioimpedance testing separates fat mass, lean mass, and visceral fat distribution in more detail than waist circumference can. Pilot research supports combining bioimpedance with blood biochemistry to build a more complete metabolic picture.
Some wellness studios sell body composition scans as a standalone purchase. In a clinical workup, the scan is one input among several and is interpreted alongside the blood markers.
The 2026 AHA/ACC Cardiovascular-Kidney-Metabolic (CKM) Staging Framework
The CKM framework provides the clinical context that turns a list of numbers into a risk stage.
The American Heart Association introduced it in 2023 as a staged model running from Stage 0 to Stage 4. It treats metabolic risk as a progressive, multi-organ continuum instead of a yes-or-no diagnosis. On June 9, 2026, the first joint ACC/AHA clinical guideline formalized how CKM is staged and managed.
The framework addresses a very large population. Nearly 90% of US adults have at least one CKM risk factor, and obesity alone affects about 40% of adults.
What the Stages Mean in Practice
The stages run from no risk factors at Stage 0 to advanced cardiovascular-kidney-metabolic disease at Stage 4. A patient’s placement depends on the five core markers combined with the extended workup results.
Two people with similar lab numbers can land in different stages because of differences in blood pressure trends, kidney markers, or medical history. Placing someone accurately requires a clinician, not a scorecard.
How Staging Changes Screening Frequency and Next Steps
AHA guidance links screening frequency to stage:
| CKM Stage | Recommended Screening |
|---|---|
| Stage 0 | Every 3 to 5 years |
| Stage 1 | Every 2 to 3 years |
| Stage 2 or higher | Annually |
A one-size-fits-all annual panel does not reflect this approach. The right frequency depends on a person’s stage, and determining the stage requires a clinical assessment first.
Why a Panel of Numbers Isn’t a Diagnosis
Direct-to-consumer panels are often marketed at 100 to 160 or more biomarkers. They typically come with algorithm-generated or templated commentary rather than interpretation from a licensed clinician who knows the patient’s context.
The professional literature identifies several gaps:
- No pretest probability assessment. A critique in Clinical Chemistry notes that DTC testing skips the step where a physician judges whether a test is appropriate before ordering it. As a result, tests may be run on the wrong population or read without regard to medications, symptoms, or history.
- Markers read in isolation. Physician commentary points out that interdependent markers such as insulin, HbA1c, and triglycerides need to be read together to form an actionable plan.
- Generic interpretation. Population-based explanations can create false reassurance or unnecessary anxiety.
A long list of biomarkers answers the question “What are my numbers?” It does not answer “What do they mean for me, and what should I do next?” That second question is a clinical one.
What Happens After the Results: In-Person Interpretation and Building a Plan
A provider reviews results alongside physical exam findings, medical history, medications, and symptoms before drawing conclusions from any single marker. CKM staging and the extended workup then come together in a written risk picture the patient can understand, instead of a spreadsheet of flagged values.
The plan that follows uses tools matched to the findings:
- Nutrition strategy
- Physical activity
- Hormone considerations
- Medication such as a GLP-1 medication, where clinically appropriate
Medication is one tool within the plan. The structure, clinical support, and ongoing monitoring around it are what sustain results.
What to Expect at a Clinically-Supervised Metabolic Health Assessment
At Red Mountain, the assessment belongs to the Foundation stage of care. The visit generally follows these steps:
- Intake and history review, covering symptoms, medications, and family history
- In-person measurements of blood pressure and waist circumference, taken by trained staff
- Blood draw for the core panel, plus extended markers as indicated
- Physical exam
- Follow-up conversation to review the staged results
Red Mountain has brick-and-mortar clinics and more than 30 years of patient outcomes. That in-person structure is the main difference from a mailed kit. The assessment answers the question “Why isn’t what I’m doing working anymore?” It also sets the baseline for ongoing monitoring, making it the start of care rather than a one-time test.
Who Should Get a Formal Metabolic Health Assessment, and How Often
An assessment is worth considering for anyone who has:
- A borderline lab result
- Unexplained changes in weight or energy
- A family history of diabetes or heart disease
- Passed age 40 without a comprehensive evaluation in several years
How often to repeat it follows the CKM schedule: every 3 to 5 years at Stage 0, every 2 to 3 years at Stage 1, and annually at Stage 2 or higher. Following that schedule requires knowing one’s stage, which in turn requires an assessment.
This is a mainstream health concern. Prevalence is rising among adults 60 and older and among non-Hispanic Black individuals. Worldwide, metabolic syndrome prevalence has roughly doubled since 2000 and now affects about 1.54 billion adults.
Conclusion: A Number Isn’t a Diagnosis, Interpretation Is
The number of biomarkers tested does not define a true metabolic health assessment. What defines it is whether a clinician stages the results and builds a plan around them.
The five core markers, the extended workup, and CKM staging together form a complete clinical picture that a list of 100 or more test results cannot replace. At Red Mountain, the Foundation assessment is the starting point for correcting root causes. It leads into the longer-term work of the Function, Confidence, and Longevity stages.
Next Step: Getting a Clear Picture of Where You Stand
A borderline result, unexplained symptoms, a family history, or simple uncertainty about one’s numbers are all reasonable reasons to get assessed. Red Mountain’s consults are where these results are explained and staged, with no obligation to commit to anything. For many people, that conversation is the most useful next step.
